6 ms·
The article didn't focus too much on solutions, though a couple of things were mentioned: 1. Reducing patent protection 2. Price controls (?) So let's assume w
by dleavitt 3y ago
The article didn't focus too much on solutions, though a couple of things were mentioned:
1. Reducing patent protection
2. Price controls (?)
So let's assume we want these companies to reduce their profit margins (and instead lower drug prices or spend more on R&D.) What _are_ the best policy tools to incentivize this while minimizing market distortions, etc?
- ajmurmann 3y agoWouldn't both reduced patent protections and price controls reduce incentive to invest in R&D and for private investors likewise reduce incentive to invest in pharma that invests in R&D?